Genetic bottlenecks in intercellular communication and the blind spot of exosome cargo-mediated post-transcriptional regulation Malignant tumors, beyond the intrinsic proliferation of cancer cells, continuously reprogram the tumor microenvironment (TME) to their advantage through molecular signaling crosstalk with surrounding stromal and immune cells. Central to this horizontal transfer of genetic information are exosomes—nanovesicles ranging from 30 to 150 nm. Tumor-derived exosomes carry active epigenetic cargo such as microRNAs (miRNA), long non‑coding RNAs (lncRNA), circular RNAs (circRNA), and messenger RNAs (mRNA), remotely controlling gene expression in recipient cells at the post‑transcriptional level. By inducing mRNA degradation, inhibiting translation, disrupting alternative splicing, and promoting epigenetic remodeling, these vesicles disseminate angiogenesis, metastasis, immune evasion, and persistent drug resistance, representing a critical technical bottleneck that limits the efficacy of conventional anticancer therapies in halting tumor evolution.

Multidimensional exosome communication blockade pipeline: from biogenesis inhibition to Cas13 RNA editing To fundamentally disrupt the malignant molecular network among cancer cells, we established an integrated blockade framework that artificially stratifies exosome biogenesis through release and transport pathways. The team employed the small‑molecule GW4869 and Rab GTPase modulators to clamp intracellular exosome production and membrane fusion release to a statistical baseline. Simultaneously, we obstructed uptake pathways into target cells and neutralized the oncogenic genomic payload of already released exosomes using antisense oligonucleotides (ASO), RNA interference (RNAi), and next‑generation CRISPR/Cas13 RNA‑editing constructs. This multiplexed inhibition protocol acts as a potent engineered lever, programmably silencing downstream oncogenic signaling cascades such as PI3K/AKT, JAK/STAT, and Wnt/β‑catenin.

Biocompatible engineered exosome architecture: blocking stromal cell transformation and reversing immunosuppressive environments The translational highlight of this work is the counterintuitive reprogramming of the natural nanocarrier backbone of exosomes into a high‑efficiency, biocompatible drug‑delivery system (DDS). Unlike synthetic liposomes or lipid nanoparticles (LNPs), engineered exosomes retain an intrinsic immune‑evading profile, resulting in maximized in‑vivo half‑life and unparalleled targeting specificity. The team densely packaged siRNA, miRNA mimics, mRNA, and CRISPR protein cassettes within these synthetic exosomes and delivered them precisely into the TME. Consequently, the pathway converting normal fibroblasts into cancer‑associated fibroblasts (CAF) was blocked, the polarization threshold of immunosuppressive M2 macrophages was fully reversed, and pre‑metastatic niche formation was abrogated, thereby achieving complete control over metastatic kinetics.

Establishment of a precision oncology platform and enterprise‑scale manufacturing standardization The data white paper on post‑transcriptional genome regulation and vesicle engineering delivers a disruptive impact on the global biopharma R&D landscape and the cell‑ and gene‑therapy sector. By resetting cancer‑treatment guidelines from mere induction of cellular toxicity to the blockade of exosome‑mediated horizontal genetic signaling and activation of natural bio‑chips, the paradigm shifts dramatically. Nevertheless, commercial translation requires overcoming engineering challenges such as large‑scale high‑purity manufacturing, standardized isolation, and biosafety testing. By reverse‑engineering exosomal RNA profiles from patient blood, we can derive multi‑gene scores predicting drug resistance and automatically design personalized inhibitory modalities, forming a standard reference asset that will power next‑generation precision oncology SaaS pipelines.